Invest Securities confirms its Buy rating on Transgene shares, with an unchanged target price of 5.7 euros.

On Friday, the company announced that a new drug candidate from its OV (oncolytic virus) franchise was entering clinical trials, reports the research house.

This is the 4th OV developed by Transgene to reach the clinical trial stage, and the 3rd from the InVir.IO. platform", adds the broker, who also points out that this OV can be administered intravenously, making its use "judicious for a panel of hard-to-reach cancers".

According to Invest Securities, the 1st patient in the Phase I trial recently authorized by the ANSM is expected to be enrolled in the first half of 2023, to assess TG6050's potential in advanced diffuse NSCLC (Non-Small Cell Bronchial Cancer).


Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.